Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 inactivated vaccine (Vero cell)
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
COVID-19 Inactivated Vaccine (Vero Cell) refers to a group of inactivated whole-virus vaccines developed to prevent COVID-19. These vaccines are produced by propagating the SARS-CoV-2 virus in Vero cell cultures, followed by chemical inactivation (typically with beta-propiolactone) and purification. The resulting inactivated virus particles are formulated with an aluminum hydroxide adjuvant to enhance immunogenicity. Upon intramuscular administration, the vaccine presents the entire array of viral proteins—including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins—to the immune system, inducing the production of neutralizing antibodies and T-cell responses. Prominent examples include the BIBP vaccine (COVILO) and the Sinovac vaccine (CoronaVac), both of which received WHO Emergency Use Listing.
- Brand names
- COVILOCoronaVac
- Other names
- Sinopharm COVID-19 vaccineSinovac COVID-19 vaccineBIBP vaccineWIBP vaccineMinhai COVID-19 vaccineInactivated SARS-CoV-2 Vaccine (Vero Cell)
02
Targets
SARS-CoV-2 envelope and membrane proteinspp1a (Replicase polyprotein 1a)N (Nucleocapsid protein)RBD (SARS-CoV-2 spike receptor-binding domain)E (Tick-borne encephalitis virus envelope protein)M protein (SARS-CoV-2 membrane protein)
Beyond the preview
Go deeper on COVID-19 inactivated vaccine (Vero cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 inactivated vaccine (Vero cell).